PF-Atlas › Treatments
IPF Treatments & Therapies (35)
Every idiopathic pulmonary fibrosis treatment tracked by PF-Atlas — FDA-approved antifibrotics, Phase III candidates, and emerging regenerative therapies. Ranked by evidence and modeled impact. Each links to trials, mechanism, and research.
- 1. Nerandomilast / Jascayd Clinically established FDA Approved Oct 2025
- 2. Inhaled Treprostinil / Tyvaso Clinically established Phase III (FDA filing 2026)
- 3. Admilparant / BMS-986278 Clinically established Phase III (ALOFT-IPF)
- 4. Rentosertib / ISM001-055 Clinical research Phase IIa (Nature Medicine 2025)
- 5. AI Knowledge Graph PF-Atlas model Available Now
- 6. uPAR-CAR-T Senolytic Immunotherapy Clinical research Preclinical (MSK)
- 7. Senolytics + WNT Agonist Combination Clinical research Concept/Preclinical
- 8. PMFF-Net AI Diagnostic PF-Atlas model Available Now
- 9. Lung-on-Chip + AI Drug Screening PF-Atlas model Available Now
- 10. LNP-mRNA Lung-Targeted Gene Delivery Clinical research Phase I (multiple)
- 11. CRISPR Base Editing for AATD/Lung Disease Clinical research Phase I (Beam/Prime)
- 12. CAR-T Anti-FAP Fibroblasts Clinical research Preclinical
- 13. GLP-1 Agonist Anti-Fibrotic Repurposing Clinical research Phase I/II (repurposing)
- 14. Dendritic Cell Immunotherapy Clinical research Phase I/II (Germany)
- 15. WNT/RSPO3 Agonist Clinical research Phase I IND
- 16. Dasatinib + Quercetin Clinical research Phase II
- 17. PLN-74809 Clinical research Phase II/III
- 18. Rapamycin/mTOR Inhibition Clinical research Phase I/II
- 19. CD49a+ Tissue Resident Memory T-Cell Therapy Clinical research Preclinical
- 20. Ruxolitinib Clinical research Phase I/II
- 21. Liver Fibrosis Reversal Protocol Crossover Clinical research Translational
- 22. Inhaled GSK3008348 Clinical research Phase II
- 23. OSK Partial Reprogramming of AEC2s Clinical research Preclinical
- 24. Galectin-3 Inhibition Clinical research Phase II
- 25. Lipofibroblast Niche Restoration Clinical research Preclinical
- 26. Navitoclax Clinical research Phase II
- 27. ROCK Inhibitor — Inhaled Fasudil Clinical research Phase II
- 28. Aberrant Basaloid Cell Elimination Clinical research Preclinical
- 29. YAP/TAZ Inhibition Clinical research Preclinical
- 30. TERT Gene Therapy Clinical research Preclinical→Phase I
- 31. Macrophage M2 Reprogramming Clinical research Preclinical
- 32. iPSC-Derived AEC2 Transplant Clinical research Preclinical
- 33. NAD+/NMN Supplementation Clinical research Phase I/II
- 34. Mocetinostat Clinical research Phase II
- 35. MSC-Derived Extracellular Vesicles Clinical research Phase I
Medical disclaimer. PF-Atlas is a computational research atlas, not a medical provider. Rankings reflect published evidence and model output for information only, and are not medical advice. Consult a pulmonologist before any treatment decision.